Drugs / LUCORAFUSP ALFA
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05653284 | Feb → Dec 2023 | cancer | Akeso | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06938321 | Apr 2025 → May 2027 expected | biliary tract cancer | Akeso | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06530251 | Sep 2024 → Jun 2026 overdue | hepatocellular carcinoma | Akeso | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07114315 | Sep 2025 → Aug 2027 expected | malignant pancreatic neoplasm | Akeso | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2026-06-09 | Akeso | Results 四靶点协同抗肿瘤！康方首创TIGIT/TGF-β双靶点抗体融合蛋白联合依沃西后线治疗胆道癌优异数据发布|ASCO2026 akesobio.com ↗
45mg/kg Q3W（推荐的II期研究剂量，RP2D）组ORR为25.0%，DCR为68.8%；且获得疾病控制的患者中，85.7%观察到肿瘤明显退缩； |
| 2024-01-15 | Akeso | Regulatory 康方PD-1/VEGF双抗依沃西联合卡度尼利/AK130/AK127治疗肝细胞癌Ⅰb/Ⅱ期临床研究获批 akesobio.com ↗ |
| 2022-11-17 | Akeso | Regulatory 首创双靶点抗体融合蛋白IND，康方AK130（TIGIT/TGF-β）治疗晚期恶性肿瘤获批临床 akesobio.com ↗
近日，康方生物全球首创的TIGIT/TGF-β双靶点抗体融合蛋白（AK130），获得国家药品监督管理局药品审评中心的临床试验默示许可，开展治疗晚期恶性肿瘤的临床试验. |
| 2022-09-13 | Akeso | Results 康方全球首创TIGIT/TGF-β双靶点抗体融合蛋白临床前研究成果首次公布 akesobio.com ↗
临床前研究显示：AK130可特异性结合人TIGIT和TGF-β且具有高亲和力. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-06-09 | Akeso | 四靶点协同抗肿瘤！康方首创TIGIT/TGF-β双靶点抗体融合蛋白联合依沃西后线治疗胆道癌优异数据发布|ASCO2026 akesobio.com ↗ |
| 2024-01-15 | Akeso | 康方PD-1/VEGF双抗依沃西联合卡度尼利/AK130/AK127治疗肝细胞癌Ⅰb/Ⅱ期临床研究获批 akesobio.com ↗ |
| 2022-11-17 | Akeso | 首创双靶点抗体融合蛋白IND，康方AK130（TIGIT/TGF-β）治疗晚期恶性肿瘤获批临床 akesobio.com ↗ |
| 2022-09-13 | Akeso | 康方全球首创TIGIT/TGF-β双靶点抗体融合蛋白临床前研究成果首次公布 akesobio.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LUCORAFUSP ALFA | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068134 ↗ |
| Known as | AK130 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07114315 ↗ |
| Modality | Protein / enzyme biologic | “AK130 (TIGIT/TGF-β bifunctional fusion protein)” NCT05653284 ↗ |
| Route | Intravenous | “IV infusion, specified dose on specified days.” NCT05653284 ↗ |